IngredientsValine (abbreviated as Val or V) is an Ξ±-amino acid with the chemical formula HO2CCH(NH2)CH(CH3)2. More formally, L-Valine is chemically known as (2S)-2-amino-3-methylbutanoic acid, an alpha-amino acid with the side chain βCH(CH3)2. Its molecular formula is Cβ HββNOβ, and its molar mass is 117.148 g/mol, and the melting point is 315 Β°C.
The chirality of the molecule, denoted by the 'L-' prefix, refers to its specific spatial arrangement, which is the biologically active form in most organisms. In practical terms, in L-valine, 'L' signifies the laevorotatory nature of valine. The molecule is classified in multiple ways: valine is an aliphatic, non-polar, non-aromatic, branched chain, glycogenic, essential, and alpha (Ξ±-) amino acid that is not synthesized by the human body.
Along with leucine and isoleucine, valine is a branched-chain amino acid, and it is named after the plant valerian. More precisely, the name valine comes from its structural similarity to valeric acid, which in turn is named after the plant valerian due to the presence of the acid in the roots of the plant.
At the molecular structural level, the central alpha carbon atom is attached to a carboxylic acid moiety (βCOOH), an amino group (βNHβ), a hydrogen atom (βH), and an isopropyl R side chain (βCH(CHβ)β). This branched side chain renders valine hydrophobic: it has a hydrophobic side chain, which leads to a small dipole moment, thus showing repulsion to water.
L-Valine is one of 20 proteinogenic amino acids, and its codons are GUU, GUC, GUA, and GUG.
Valine (Val/V) was first isolated from casein (a milk protein) in 1901 by German chemist Hermann Emil Fischer. Fischer, the famous German chemist who was also awarded the Nobel Prize in Chemistry in 1902, first isolated valine from casein protein. The compound was obtained, in the words of Britannica, by hydrolysis of proteins.
Valine, like other branched-chain amino acids, is synthesized by bacteria and plants, but not by animals. It is therefore an essential amino acid in animals and needs to be present in the diet. In plants and microorganisms, it is synthesized from pyruvic acid, a product of the breakdown of carbohydrates. At the enzymatic level in microorganisms, pyruvate is used as a direct precursor in the synthesis branch of L-valine, undergoing four steps of reaction catalyzed by acetolactate synthase, acetohydroxyacid isomeroreductase, dihydroxyacid dehydratase, and branched-chain amino acid transaminase to finally produce L-valine.
In its pure form, L-valine appears as a white or almost white, crystalline powder or colourless crystals, soluble in water, and very slightly soluble in alcohol. The proteins in foods from animal and plant sources typically contain about 40β60 mg/g Val. Dietary supplements with crystalline Val, often in combination with other amino acids, are commercially available.
Industrial production of L-valine has historically relied on fermentation: traditional industrial fermentative production of BCAAs was performed using microorganisms isolated by random mutagenesis. Supplemental L-valine is most commonly encountered as free-form crystalline powder in capsule or loose powder form, as tablets, and as a component of combined BCAA supplements in ratios alongside leucine and isoleucine. Because of its importance in pharmacological nutrients for patients with chronic liver illness and its high tolerance for the production and breakdown of muscle protein, L-valine finds extensive application in the pharmaceutical sector as an ingredient in third-generation amino acid infusions. It is also used in the food industry as a flavor compound, and enhancing the moisturizing function and collagen synthesis of cosmetics is possible with the addition of L-valine.
It is one of the essential amino acids, meaning it cannot be synthesized by the human body and must be obtained through diet or supplements. Valine is essential in humans and must be obtained from dietary sources, which are foods that contain proteins, such as meats, dairy products, soy products, beans, and legumes. More specifically, high valine foods include beef, chicken, pork, fish, tofu, yogurt, beans, podded peas, seeds, nuts, and whole grains like oatmeal.
For those following plant-based diets, vegans can get their valine intake from a variety of plant-based sources such as soy products, seeds, nuts, and legumes, and ensuring a well-rounded and diverse vegan diet can help meet the body's valine requirements. Valine content across food categories is broad: the proteins in foods from animal and plant sources typically contain about 40β60 mg/g Val.
L-Valine, as an isolated chemical entity, has no traditional botanical or herbal use per se β it is an amino acid constituent of all dietary proteins rather than a medicinal plant extract with documented traditional use in specific healing systems. Its "traditional use" context therefore corresponds to the documented history of protein-rich foods in various cultures and the scientific recognition of amino acids as therapeutic nutritional agents in the 20th century.
The broader category of branched-chain amino acids, including valine, first attracted clinical interest in the context of liver disease in the mid-20th century. Branched-chain amino acids (BCAAs: isoleucine, leucine, and valine) attracted particular interest and in 1956 MΓΌting described the amino acid pattern in patients with cirrhosis. The abnormal plasma pattern has been characterized by the ratio between BCAA and aromatic amino acids in plasma, the so-called 'Fischer's ratio,' which has been associated with the grade of hepatic encephalopathy.
The nutritional sciences established early that severe or prolonged dietary insufficiency of protein (and thus valine) was deleterious. Prolonged lack of valine, as of all essential amino acids, or a lack of protein causes growth failure, loss of muscle mass, and organ damage. The first systematic evidence-based clinical use of BCAA formulations, including valine, arose in the treatment of liver disease in the late 1970s and early 1980s, when researchers found that intravenous BCAA-enriched solutions could benefit patients with hepatic encephalopathy who could not tolerate sufficient dietary protein.
In the early 1980s, a randomized study evaluated the effect of BCAAs in protein-intolerant cirrhotic patients. Enrolled subjects were fed with increasing amounts of either dietary protein or a BCAA solution until they attained an intake of 80 g protein per day or until they developed stage 2 encephalopathy. Oral BCAA supplements induced a positive nitrogen balance equivalent to an equal amount of dietary protein but decreased the risk of HE recurrence.
The popularity of BCAA supplementation β with valine as a standard component β among athletes and bodybuilders grew substantially from the 1980s onward, based on the hypothesis that supplemental BCAAs could spare muscle protein during exercise and support recovery. Branched-chain amino acids (BCAA: leucine, isoleucine, and valine) are three of the nine indispensable amino acids, and are frequently consumed as a dietary supplement by athletes and recreationally active individuals alike. The popularity of BCAA supplements is largely predicated on the notion that they can stimulate rates of muscle protein synthesis (MPS) and suppress rates of muscle protein breakdown (MPB), the combination of which promotes a net anabolic response in skeletal muscle.
In protein synthesis, L-valine is incorporated into polypeptide chains, contributing to the structural integrity and functional diversity of proteins. Its branched side chain influences protein folding and stability. More specifically, its bulkiness near the protein backbone causes it to adopt main-chain and alpha-helical conformations; it lies within beta-sheets easily.
A clinically notable consequence of valine's structural role is its involvement in sickle-cell disease. In sickle-cell disease, valine substitutes for the hydrophilic amino acid glutamic acid in hemoglobin. Because valine is hydrophobic, the hemoglobin is prone to abnormal aggregation.
The essential amino acid L-valine is needed for the synthesis of proteins. It is also used as an energy fuel; its complete oxidation requires thiamin, riboflavin, niacin, vitamin B6, vitamin B12, pantothenate, biotin, lipoate, ubiquinone, magnesium, and iron.
Valine is a glycogenic amino acid, because it can be converted to glucose via the gluconeogenesis process in the liver. More broadly, it serves as a precursor for the synthesis of other amino acids and plays a role in gluconeogenesis, the process by which glucose is synthesized from non-carbohydrate sources, providing an important energy source especially during prolonged physical activity.
Valine is absorbed in the small intestine and metabolized mainly in muscle to yield Ξ±-ketoisovalerate (a branched-chain ketoacid, BCKA) and glutamic acid under the catalysis of aminotransferase. More broadly, once inside the cell, BCAAs are reversibly transaminated by branched-chain amino acid transferases (BCATs) to yield corresponding branched-chain Ξ±-ketoacids (BCKAs); BCATs use Ξ±-ketoglutarate as the amino acceptor, producing glutamate in the process. Humans have two BCAT isoforms with distinct localization: cytosolic BCAT1 and mitochondrial BCAT2. Subsequently, BCKAs are oxidized by branched-chain Ξ±-keto acid dehydrogenase (BCKDH), regulated by kinase BCKDK and phosphatase PPM1K, producing acetyl-CoA and intermediates for the tricarboxylic acid (TCA) cycle.
BCAAs are absorbed from the gastrointestinal tract through active transport mechanisms. After ingestion, they enter the bloodstream and are taken up by tissues, primarily skeletal muscle, via specific amino acid transporters such as System L (LAT1). This system is sodium-independent and facilitates the uptake of neutral amino acids, including BCAAs.
BCAAs (leucine, isoleucine, and valine), particularly leucine, have anabolic effects on protein metabolism by increasing the rate of protein synthesis and decreasing the rate of protein degradation in resting human muscle. At the molecular level, these effects are likely to be mediated through changes in signaling pathways controlling protein synthesis, involving phosphorylation of the mammalian target of rapamycin (mTOR) and sequential activation of 70-kD S6 protein kinase (p70 S6 kinase) and the eukaryotic initiation factor 4E-binding protein 1.
It is important to note that valine's signaling role differs from that of leucine in this context. Leucine can be sensed and activate the global anabolic regulator mTORC1 through Sestrin2 and the leucine-tRNA synthetase, with isoleucine acting as a weak mTORC1 agonist. In contrast, direct sensors or even direct downstream molecular mechanisms for valine-regulated biology remain unknown.
Valine competes with other amino acids, such as tryptophan, for entry into the brain, which may help reduce the synthesis of serotonin and delay fatigue during physical activity. This competition occurs because valine and tryptophan share the same large neutral amino acid (LNAA) transport system across the blood-brain barrier; when valine levels are elevated in the bloodstream, less tryptophan enters the brain, and central serotonin synthesis is attenuated, theoretically delaying the onset of central fatigue during prolonged exercise. Evidence in humans for this mechanism is discussed further in the section on exercise performance.
Valine plays a crucial role in improvement of cellular mitochondrial function, has a protective effect against oxidative stress by minimizing the production of mitochondrial ROS, and maintains oxidative phosphorylation and ATP rate during oxidative stress. In a cell line study using C2C12 skeletal muscle cells, cells treated with a 1.0 mM concentration of valine for 24 h showed increased gene expression of PGC-1Ξ±, PGC-1Ξ², and mitochondrial fission and fusion genes. These findings are preliminary and derived from in vitro work rather than human trials.
Val is uniquely required for proliferation and maintenance of hematopoietic stem cells in vitro and in vivo, as well as for the growth of T cell acute lymphoblastic leukemia (T-ALL). Animal research has demonstrated this with notable specificity: dietary valine is essential for hematopoietic stem cell (HSC) self-renewal, as demonstrated by experiments in mice. Dietary valine restriction selectively depletes long-term repopulating HSC in mouse bone marrow. Successful stem cell transplantation was achieved in mice without irradiation after 3 weeks on a valine-restricted diet. These findings remain in the preclinical stage and have not been validated in human transplantation protocols.
The importance of valine for the stimulation of the immune response is supported by a report by Kakazu et al., in which they describe the critical role of Val in the maturation of dendritic cells. These findings indicate that Val may have therapeutic potential for reducing hepatocarcinogenesis in patients with cirrhosis by restoring immune functions.
The valine catabolite 3-hydroxyisobutyrate (3-HIB) promotes insulin resistance in mice by stimulating fatty acid uptake into muscle and lipid accumulation. This catabolite has attracted significant research attention as a possible mechanistic link between elevated circulating valine and metabolic disease, discussed further in the safety section.
Overview: The majority of research on valine as a supplement has been conducted in the context of BCAA mixtures rather than valine in isolation. The evidence base for combined BCAA supplementation is substantially larger than for valine alone, and most findings attributed to "valine" in this literature reflect the combined actions of leucine, isoleucine, and valine.
Muscle Protein Synthesis: Several studies have shown that BCAA (particularly leucine) increase the phosphorylation status of key proteins within the mechanistic target of rapamycin (mTOR) signalling pathway involved in the regulation of translation initiation in human muscle. Early research in humans demonstrated that BCAA provision reduced indices of whole-body protein breakdown and MPB; however, there was no stimulatory effect of BCAA on MPS. In contrast, recent work has demonstrated that BCAA intake can stimulate postprandial MPS rates at rest and can further increase MPS rates during recovery after a bout of resistance exercise. Importantly, BCAA can activate molecular pathways that regulate translation initiation, reduce indices of whole-body and muscle protein breakdown, and transiently stimulate MPS rates. However, the stimulatory effect of BCAA on MPS rates is less than the response observed following ingestion of a complete protein source providing the full complement of indispensable amino acids.
Exercise-Induced Muscle Damage and Soreness (Meta-analytic Evidence): A meta-analysis published in 2017 included eight randomized controlled trials and found that pooled data from the eight studies showed that BCAAs significantly reduced creatine kinase at two follow-up times (<24 h and 24 h) in comparison with placebo recovery (<24 h: mean difference, β71.55 U/L, 95% confidence interval, β93.49 to β49.60, P < 0.000, n = 5 trials; 24 h: mean difference, β145.04 U/L, 95% confidence interval, β253.66 to β36.43, P = 0.009, n = 8 trials). The overall conclusion was that the current evidence-based information indicates that use of BCAAs is better than passive recovery or rest after various forms of exhaustive and damaging exercise. The advantages relate to a reduction in muscle soreness and ameliorated muscle function because of an attenuation of muscle strength and muscle power loss after exercise.
Systematic Review (2021): A systematic review of 19 studies using the PubMed/MEDLINE, Scopus, and Web of Science databases concluded that the most optimal regimen for post-exercise muscle recovery and/or muscle function after high-intensity resistance exercise was 2β10 g BCAA/day (leucine:isoleucine:valine at 2:1:1), consumed as a supplement alone or combined with arginine and carbohydrates, 3 previous days before exercise, immediately before and after exercise, regardless of training level. This treatment can improve perceived muscle damage, fatigue, circumference of arm/leg, counter movement jump, maximum muscle strength and maximum voluntary contraction, and reduce creatine kinase and lactate dehydrogenase levels, mainly in young males. Conclusions: intake of BCAA favors post-exercise muscle recovery and may improve muscle function.
Systematic Review (2025): A more recent systematic review searched databases through August 2025 and included 22 studies with 511 participants, with daily doses ranging from 1.5 g to 82 g. The results moderately support BCAA reducing muscle soreness; however, there is inconsistent evidence to support BCAAs having an ergogenic effect on strength and endurance. Due to unclear/high risk of bias in several studies, no meta-analysis was performed. In conclusion, BCAA supplementation may reduce muscle soreness post-exercise, but evidence for improvements in strength, endurance, and body composition remains inconsistent.
Sex-Based Differences: A six-month randomized controlled trial examined sex-based responses to BCAA supplementation. Subjects in the BCAA group took five daily capsules of 500 mg L-leucine, 250 mg L-isoleucine, and 250 mg L-valine for six months. Notable findings include significant improvements in muscle recovery, as indicated by reduced DOMS, particularly in women who showed a decrement of 18.1 Β± 9.4 mm compared to 0.8 Β± 1.2 mm in the placebo group. Fatigue perception was also significantly lower in the BCAA group, with women reporting a greater decrease. Strength gains were prominent, especially in men, with a 10% increase in bench press maximum observed in the BCAA group. The interaction between sex and treatment was significant, suggesting sex-specific responses to BCAA supplementation.
Central Fatigue β Exercise Study: A crossover trial in 16 male long-distance runners investigated BCAA effects on muscular and central fatigue. Athletes ingested 20 g of BCAAs dissolved in 400 ml of water and 200 ml of strawberry juice one hour prior to the start of the incremental exercise protocol. Each gram of BCAAs supplement contained 300 mg of valine, 250 mg of leucine, and 100 mg of isoleucine. The study measured creatine kinase, myoglobin, and serotonin to assess muscular and central fatigue, respectively.
Evidence Strength: Evidence for BCAA (including valine) supplementation reducing exercise-induced muscle soreness and damage biomarkers is moderate to moderately strong based on multiple RCTs and meta-analyses. Evidence for ergogenic effects on strength or endurance is inconsistent and currently insufficient to draw firm conclusions. Critically, nearly all positive findings pertain to combined BCAA mixtures, not to valine in isolation. The independent contribution of valine to these outcomes has not been established in controlled human trials.
Serum levels of branched-chain amino acids (BCAAs) are decreased in patients with liver cirrhosis. The imbalance of amino acids levels has been suggested to be associated with the development of complications, such as hepatic encephalopathy and sarcopenia, and to affect the clinical presentation and prognosis of these patients.
It is now believed that the beneficial effect of BCAA is associated with ammonia detoxification outside the liver, predominantly in muscles. When the liver fails, the homeostasis is altered and muscle tissue becomes the main alternative organ for at least temporary detoxification of ammonia. BCAAs are believed to support this muscle ammonia detoxification and the ammonia-lowering effect of BCAAs has been intensely investigated.
In patients with advanced chronic liver disease, BCAA concentrations are low, whereas the concentrations of aromatic amino acids (AAA) such as phenylalanine and tyrosine are high, conditions that may be closely associated with hepatic encephalopathy (HE).
Cochrane Review: A Cochrane systematic review including 11 randomised clinical trials on BCAA versus control interventions evaluated if BCAA may benefit people with hepatic encephalopathy. The evidence shows that BCAAs had a beneficial effect on manifestations of HE, including overt hepatic encephalopathy (RR = 0.73, 95% CI 0.61β0.88), but not minimal hepatic encephalopathy. Overall, the evidence suggests BCAAs reduce hepatic encephalopathy, but the certainty of evidence is low. It is not known whether BCAAs, compared with controls, have any effect on all-cause mortality, nausea and diarrhoea, albumin, and nitrogen balance because of very low-certainty evidence.
A large-scale multicenter RCT in cirrhotic patients is notable: a multicenter, randomized, and nutrient-intake-controlled trial on the comparative effects of BCAA orally administered at 12 g/day for 2 years vs. non-BCAA-supplemented diet therapy was conducted in 646 patients with cirrhosis. The primary end point was a composite of death by any cause, development of liver cancer, rupture of esophageal varices, or progress of hepatic failure (event-free survival).
The current international guidelines for the treatment of hepatic encephalopathy (HE) suggest that BCAAs have a beneficial effect on HE and can be used as second-line therapy in patients with HE not responding to conventional therapy. However, the use of BCAA supplementation in clinical practice remains controversial, in particular with regards to the optimal dose, duration, and relative concentration of amino acids, as there was significant variability across the studies.
Evidence Strength: Moderate evidence (low-certainty per Cochrane) for BCAA β including valine as a component β in reducing overt hepatic encephalopathy episodes. International guidelines support BCAA use as second-line therapy for HE. Evidence for broader liver disease endpoints (mortality, liver cancer prevention) is insufficient and inconsistent.
Clinically, BCAAs intake has been suggested to reduce sarcopenia in older adults and possibly improve glucose metabolism, potentially by increasing mitochondrial biogenesis and muscle cellular function. This area of research is emerging, and most available evidence is derived from BCAA combination studies with older adults or from basic science rather than from dedicated valine-specific RCTs. Evidence strength is preliminary.
The relationship between L-valine (as part of elevated circulating BCAAs) and glucose metabolism is complex and bidirectional, representing one of the most actively debated areas in BCAA research.
Epidemiological Associations: Multiple large observational studies have linked elevated circulating BCAA levels (including valine) with insulin resistance and type 2 diabetes risk. In the Insulin Resistance Atherosclerosis Study (IRAS) of 685 participants, plasma BCAAs (sum of valine, leucine, and isoleucine) were measured by mass spectrometry. Elevated plasma BCAAs were inversely associated with insulin sensitivity and insulin clearance (MCRI) and positively associated with fasting insulin in regression models adjusted for potential confounders (Ξ² = β0.0012 [95% CI β0.0018, β0.00059], P < 0.001 for SI). Furthermore, elevated plasma BCAAs were associated with incident diabetes in Caucasians and Hispanics (multivariable-adjusted odds ratio per 1-SD increase in plasma BCAAs: 1.67).
Several studies showed that plasma BCAA levels in overweight and obese humans with insulin resistance and patients with T2D were elevated compared to healthy individuals. In an observational study, this finding was confirmed, showing that plasma BCAA levels were elevated in patients with T2D compared to age- and BMI-matched controls without T2D.
Valine-Specific Mechanism (3-HIB): The valine catabolite 3-hydroxyisobutyrate (3-HIB) was shown to promote insulin resistance in skeletal muscle by increasing lipid content in vivo. This study found that 3-HIB can reduce muscle insulin sensitivity and support a role of 3-HIB in the development of insulin resistance. A cross-sectional study of newly diagnosed T2D patients found that circulating valine levels were significantly higher in T2D patients and were decreased by DPP-4i treatment, and plasma valine concentrations were closely correlated with fasting plasma glucose.
Lower levels of serum valine, like other BCAAs, are associated with weight loss and decreased insulin resistance; higher levels of valine are observed in the blood of diabetic mice, rats, and humans. Mice fed a BCAA-deprived diet for one day had improved insulin sensitivity, and feeding of a valine-deprived diet for one week significantly decreases blood glucose levels.
Complexity and Caveats: Despite many studies demonstrating the correlation between BCAAs and insulin resistance, valine was reported not to cause insulin sensitivity issues or worsen insulin resistance in some study designs. Even though BCAAs have been reported to improve metabolic health, an increased BCAA plasma level is associated with a high risk of metabolic disorder and future insulin resistance, or type 2 diabetes mellitus. The prevailing scientific interpretation is that elevated circulating BCAAs (including valine) in the context of obesity and metabolic syndrome may be a consequence of disordered catabolism rather than a primary cause of insulin resistance, though the valine catabolite 3-HIB adds a plausible mechanistic pathway. Considering the nonobvious correlation between circulating BCAA levels and BCAA uptake, as well as the influence of diseases, diet, and aging on the body, some contradictory conclusions have been drawn.
Evidence Strength: Consistent epidemiological evidence links elevated circulating valine/BCAA levels to insulin resistance and T2D risk, but causality versus correlation remains actively debated. The 3-HIB mechanism is supported by preclinical data. No RCTs have specifically tested valine supplementation on insulin sensitivity outcomes in humans.
Hematopoietic stem cells (HSCs) are used clinically in bone marrow transplantation due to their unique ability to reform the entire hematopoietic system. HSCs are highly sensitive to valine, one of the three BCAAs. Dietary depletion of valine could even be used as a conditioning regimen for HSC transplantation. This is an active preclinical research area with significant therapeutic implications, but human clinical data are not yet available. In vivo depletion of all three BCAAs was significantly less toxic than depletion of valine only, and BCAA depletion can replace valine depletion as a safer alternative to BM conditioning.
Evidence Strength: Exclusively preclinical (animal models). Human clinical translation is not yet established.
A 2023 abstract from the University of Arkansas for Medical Sciences reported that treatment of C2C12 skeletal muscle cell lines with valine at 1.0 mM for 24 hours showed increased gene expression of PGC-1Ξ±, PGC-1Ξ², and mitochondrial fission and fusion genes. The authors concluded that valine plays a crucial role in improvement of cellular mitochondrial function, has a protective effect against oxidative stress by minimizing the production of mitochondrial ROS, and maintains oxidative phosphorylation and ATP rate during oxidative stress.
Evidence Strength: In vitro only. No human clinical trials have specifically examined valine and mitochondrial outcomes.
BCAAs (valine, leucine, and isoleucine) function as nitrogen donors to generate macromolecules such as nucleotides and are indispensable for human cancer cell growth. The cell-autonomous and non-autonomous roles of altered BCAA metabolism have been implicated in cancer progression, and the key proteins in the BCAA metabolic pathway serve as possible prognostic and diagnostic biomarkers in human cancers. BCAAs serve as nitrogen donors, contributing to synthesizing macromolecules such as proteins and nucleotides crucial for cancer cell growth. BCAAs exhibit a dual role in cancer, and their effects on tumor growth or inhibition are contingent upon various conditions and concentrations.
This is a rapidly evolving area of basic science research. No clinical recommendations regarding valine supplementation in oncological contexts have been established.
According to the World Health Organization, adults need about 26 mg of valine per kg (or 12 mg per lb) of body weight daily. For example, a person weighing 70 kg (~154 pounds) should consume around 1,820 mg of valine per day. Adults are thought to require at least 20 mg/kg per day. The IOM (Institute of Medicine) 2005 report recommends for adults 1,330 mg/day valine (for a reference adult).
The Food and Nutrition Board of the Institute of Medicine set its recommendations for valine at 32 mg per gram of protein. Critically, the FNB did not establish an upper tolerable limit because adequate data from human or animal studies were lacking. This does not mean that there is no potential for adverse effects resulting from high intakes of valine from dietary supplements.
The IOM (2005) report states that there is no evidence that any amino acids including BCAA derived from usual to high intake of proteins from food will cause any adverse health effects. At supplemental doses, taking large quantities of L-valine can cause fatigue, nausea, and a lack of muscle coordination.
In general, it is reported that the complexity of amino acid metabolism, the scarcity of toxicological data, and the many reasons for the insufficiently characterised risks lead to the conclusion that it is impossible to conduct a proper risk assessment. No tolerable upper intake level has been formally established by major regulatory bodies.
Supplementing with a single amino acid in isolation β rather than as part of a complete BCAA mixture or whole protein β may create an imbalance. Excess leucine, for example, can deplete circulating isoleucine and valine: excess leucine consumption and subsequent elevation of BCAA catabolism has been shown to restrict animal growth due to systemic isoleucine and valine depletion, which could be alleviated by isoleucine/valine supplementation.
Very high intake of protein and mixed amino acids (more than three times the RDA or 2.4 g/kg) is thought to increase the risk of renal glomerular sclerosis and accelerate osteoporosis. These concerns apply to overall amino acid excess rather than valine specifically.
Maple syrup urine disease (MSUD) is a rare genetic disorder characterized by deficiency of an enzyme complex (branched-chain alpha-keto acid dehydrogenase) that is required to break down the three branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these amino acids and their toxic byproducts (ketoacids) results in the serious health problems associated with MSUD. Individuals with MSUD cannot safely consume supplemental BCAAs, including valine, outside of a strictly controlled medical protocol. The toxicity of these amino acids is restricted predominantly to leucine; indeed, extra valine and isoleucine are often given therapeutically during treatment to compete with leucine and mitigate its neurotoxic effect β but this must be done under specialist supervision.
In sickle-cell disease, valine substitutes for the hydrophilic amino acid glutamic acid in hemoglobin. Because valine is hydrophobic, the hemoglobin is prone to abnormal aggregation. This is a structural-genetic point relevant to understanding valine's biology rather than a supplementation interaction.
A ScienceDirect study in mice found that L-valine supplementation (0.30% or 0.45% in drinking water for 3 weeks) did not change body and testis weights but significantly altered morphology of Sertoli cells and germ cells within seminiferous tubules and enlarged the space between seminiferous tubules. L-valine treatment at the higher dose increased Caspase3/9 mRNA levels and CASPASE9 protein levels, inducing apoptosis of mouse testis. This is a preclinical finding requiring confirmation and should not be extrapolated to human supplementation at nutritional doses without further investigation.
As detailed in Section 5.4, elevated circulating valine concentrations are consistently associated in observational studies with markers of insulin resistance and incident type 2 diabetes. This association does not establish that valine supplementation at physiological doses increases diabetes risk, but it does support caution in populations already at elevated metabolic risk, particularly in the context of high-dose or long-term supplementation with caloric excess. High levels of circulating BCAAs in serum or plasma are thought to be associated with obesity and insulin resistance. Studies have shown that long-term exposure to high levels of BCAAs stimulates hyperlipidemia and obesity, which has a positive association with fasting glucose levels, LDL and triglyceride levels and a negative correlation with HDL-C.
Individuals with renal impairment require caution because the kidneys are responsible for clearing nitrogenous metabolites produced from amino acid catabolism. No specific study defines a threshold for L-valine in renal disease, but the general principle that high amino acid loads increase the nitrogenous burden on compromised kidneys applies.
The safety of supplemental L-valine at doses above dietary levels during pregnancy and lactation has not been established in human clinical trials. No formal safety recommendation beyond ensuring adequate dietary intake exists for these populations.
Some research has suggested a possible association between BCAA supplementation and lung failure in ALS patients; this warrants avoidance of high-dose BCAA supplementation (including valine) in this population pending further research, though the evidence is not definitive.
Health conditions that L-valine may help support.
L-Valine is a component of BCAA supplements that have demonstrated modest benefits for exercise performance in human trials. Valine competes with tryptophan for blood-brain barrier transport via the LAT1 transporter, potentially blunting central fatigue during prolonged activity. Most evidence comes from BCAA mixture trials rather than isolated valine studies. Effects are real but effect sizes are generally modest.
The relationship between L-valine and blood sugar is complex and bidirectional. Elevated circulating valine is associated with insulin resistance and type 2 diabetes risk in human epidemiological studies. Valine's catabolite 3-HIB has been shown to impair muscle insulin signaling in human subjects. Conversely, in animal models, dietary valine restriction improved glucose tolerance, suggesting valine excess may negatively affect blood sugar regulation.
L-Valine functions as a cellular energy substrate through its direct catabolism in skeletal muscle, entry into the citric acid cycle as succinyl-CoA, and contribution to gluconeogenesis. Its branched-chain structure enables bypass of hepatic processing, making it immediately available for cellular energy production. These roles are fundamental to human energy metabolism and well-documented in biochemical and clinical literature.
L-Valine is a glucogenic amino acid that can be converted to succinyl-CoA and enter the citric acid cycle, providing energy substrates during exercise and metabolic stress. Its branched-chain structure allows direct catabolism in skeletal muscle, bypassing hepatic processing. This metabolic role is well-established in human biochemistry and clinical nutrition.
Circulating valine levels are positively associated with muscle mass and strength in older adults, and BCAA supplementation (inclusive of valine) has shown benefits for sarcopenia markers in multiple clinical trials. BCAA intake is suggested to reduce sarcopenia in older adults by increasing mitochondrial biogenesis and muscle function. A large cross-sectional study (n>100,000) found valine levels mediated the relationship between total BCAAs and muscle strength.
L-Valine is an essential amino acid required for protein synthesis and skeletal muscle growth, with documented requirements established across developmental stages. BCAAs including valine are essential for normal growth and cannot be synthesized endogenously. Deficiency states (valinemia) and established dietary reference intakes confirm its obligate role in growth and development.
The relationship between L-valine and insulin sensitivity is primarily one of risk when elevated: high circulating valine is associated with insulin resistance and type 2 diabetes in multiple human cohorts. The catabolite 3-HIB impairs skeletal muscle insulin signaling and has been found elevated in human diabetic subjects. Dietary valine restriction in animal models improved insulin sensitivity, suggesting excess valine negatively modulates insulin signaling.
L-Valine is a central metabolic substrate: it is catabolized in skeletal muscle through the BCAT enzyme, contributes to gluconeogenesis, feeds the citric acid cycle as succinyl-CoA, and participates in interorgan nitrogen shuttling. Elevated circulating valine is robustly associated with insulin resistance and type 2 diabetes risk in human epidemiological studies. Its catabolite 3-hydroxyisobutyrate (3-HIB) has been shown to modulate lipid uptake in human muscle.
A 2023 study (University of Arkansas for Medical Sciences, published in PMC) found that L-valine treatment in skeletal muscle cells upregulated key mitochondrial biogenesis genes including PGC-1Ξ±, PGC-1Ξ², and mitofusin genes, and improved mitochondrial respiration. A 2024 PMC review confirmed valine improves mitochondrial function and protects against oxidative stress by modulating oxidative phosphorylation and ATP production.
L-valine is the third BCAA, catabolized in skeletal muscle as an energy substrate and nitrogen source during exercise. As a component of BCAA supplements, it contributes to documented reductions in exercise-induced muscle damage markers (CK) and DOMS shown in multiple meta-analyses of RCTs.
Human clinical trials show that BCAA supplementation including valine reduces delayed-onset muscle soreness (DOMS) and markers of muscle damage such as creatine kinase and lactate dehydrogenase following intense exercise. Effect sizes are modest and most evidence uses BCAA mixtures rather than valine alone. The 2:1:1 leucine:isoleucine:valine ratio is the most studied.
L-Valine contributes to endurance by serving as an oxidizable energy substrate during prolonged exercise when glycogen stores are depleted, and by competing with tryptophan at the blood-brain barrier to attenuate central fatigue. Human trials with BCAA preparations show improved perceived exertion and sustained performance in endurance and intermittent sprint contexts.
BCAA supplementation including valine supports recovery from illness-associated muscle wasting and nitrogen deficit. A clinical study in stroke patients found BCAA supplementation had a positive effect on sarcopenia during neurological recovery. L-valine levels are inversely correlated with sepsis severity in human patients. BCAA preparations are used in clinical nutrition for managing catabolic illness states.
BCAA supplementation including valine is used in the pharmaceutical field to maintain nitrogen balance in post-surgical patients. A 2025 propensity-score-matched clinical study demonstrated BCAA supplementation improved postoperative serum albumin recovery in older adults after hip fracture surgery. Leucine-enriched BCAA formulas containing valine stimulate hepatic protein synthesis via mTOR signaling.
Body systems that L-valine may help support.
Go back